Carl Maki to Antineoplastic Agents
This is a "connection" page, showing publications Carl Maki has written about Antineoplastic Agents.
Connection Strength
2.943
-
JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657.
Score: 0.548
-
p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340.
Score: 0.522
-
Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells. Cancer Lett. 2014 Oct 28; 353(2):290-300.
Score: 0.395
-
Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther. 2014; 15(12):1600-12.
Score: 0.380
-
Two 4N cell-cycle arrests contribute to cisplatin-resistance. PLoS One. 2013; 8(4):e59848.
Score: 0.361
-
Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des. 2011; 17(6):560-8.
Score: 0.309
-
Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. J Biol Chem. 2024 Jun; 300(6):107375.
Score: 0.195
-
The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017 Nov 02; 18(11):895-903.
Score: 0.121
-
Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016 May 10; 7(19):27511-26.
Score: 0.112